As CEO David Elsley explains, this finding not only advances our myocarditis program but also highlights the broader potential in heart failure — a condition that is an order of magnitude greater in prevalence and medical burden, representing one of modern medicine’s most pressing unmet needs.
$CRDL | #CardiolRx #Biotech #HeartHealth
https://x.com/CardiolRx/status/1983197260251799607